Endpoints NewsOriginal article
Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label
Phase 2negativeredasemtideHyrnuoNegative
AI Analysis
Summary
Shionogi's experimental stroke drug redasemtide failed to meet the primary endpoint in a mid-stage trial. Separately, Bayer's Hyrnuo received an expanded label.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Failed to meet primary endpoint
Importance:6/10
Sentiment:
-0.70
strokemid-stage trial failureredasemtidelabel expansion
Read the original article
Published by Endpoints News on September 10, 2026 3:06 PM